The aesthetic injectables market in Japan is expected to exceed US$150m in 2025, driven by the increasing number of aesthetic fillers procedures due to their superior reliability, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Aesthetic Injectables (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)’, reveals that Botulinum Toxin Type A (Botox) and Hyaluronic Acid fillers together accounted for more than 95% of the Japanese aesthetic fillers market in 2020.

Allergan Aesthetics was the leading player in 2020, followed by Galderma SA. Together these two companies accounted for around 80% of the market in 2020.

Vedant Goswami, Medical Devices Analyst at GlobalData, comments: “The aesthetic injectables market growth in Japan is driven by improved clinical outcomes and technological advancements. These procedures are easily performed since they are non-surgical and minimally invasive. Outcomes are observed in a short period of time making these procedures highly preferable.”

The growing preference to look appealing and young, especially among the entertainment, media and working population, is driving the demand for aesthetic injectables.

Mr Goswami concludes: “More than a 10 million botox procedures were performed in Japan in 2020. Botox is increasingly preferred over other types of injectables such as hyaluronic acid fillers due to their low cost. Although the hyaluronic acid fillers volumes are low compared to botox, their high cost accounted for considerable market size in Japan.”